No.	ID Internal	ID NCT	ID Cochrane	Publications	Phase	Countries/ continents	Age	Number	Reason exclusion	Safety	Efficacy
1. Bivalent vaccine
1.1. Published reports included in the Cochrane review
1	HPV‐001	NCT00689741	Phase 2 trial (v2)	Harper 2004 Harper 2006 De Carvalho 2010	IIb	Brazil, Canada, USA	16‐25y	1113	‐	+	+
2	HPV‐008	NCT00122681	PATRICIA	Paavonen 2007 Paavonen 2009 Wacholder 2010 Szarewski 2011 Wheeler 2011 Lehtinen 2012	III	America, Asia, Europe, Oceania	15‐25y	18,644	‐	+	+
3	HPV‐009	NCT00128661	CVT	Herrero 2011	III	Costa Rica	18‐25y	7466	‐	+	+
4	HPV‐013	NCT00196924 NCT00316706	immuno‐bridging (ph3,2v)	Medina 2010 Schwarz 2012	III	America, Asia, Europe, Oceania	10‐14y	2067	‐	+	_
5	HPV‐015	NCT00294047	VIVIANE	Skinner 2014	III	Europe	≥26y	5752	‐	+	+
6	HPV‐021	NCT00481767	African_2 country trial (ph3,2v)	Sow 2013	III	Africa	10‐25y	676	‐	+	‐
7	HPV‐031	NCT00344032	India trial (ph3,2v)	Bhatla 2010	III	India	18‐35y	354	‐	+	‐
8	HPV‐032	NCT00316693	Japanese trial(ph2, 2v)	Konno 2010 Konno 2010a Konno 2014	II	Japan	20‐25y	1046	‐	+	‐
9	HPV‐033	NCT00290277	Korean trial (ph3b,2v)	Kim 2010	III	Korea	10‐14y	321	‐	+	‐
10	HPV‐035	NCT00306241 NCT00811798	Hong Kong trial (ph3,2v)	Ngan 2010	III	Hong Kong	18‐35y	300	‐	+	‐
11	HPV‐036	NCT00345878	Malaysian trial (ph3,2v)	Lim 2014	III	Malaysia	18‐35y	271	‐	+	‐
12	HPV‐038	NCT00485732	Korean trial (ph3,2v)	Kim 2011	III	S‐Korea	15‐25y	225	‐	+	‐
13	HPV‐058	NCT00996125	Chinese trial (ph3,2v)_adolescent	Zhu 2014a	III	China	9‐17y	750	‐	+	‐
14	HPV‐039	NCT00779766	Chinese trial (ph3,2v)_young	Zhu 2014	III	China	18‐25y	6051	‐	+	+
15	HPV‐069	NCT01277042	Chinese trial (ph3,2v)_mid‐adult	Zhu 2014a	III	China	26‐45y	1212	‐	+	‐
1.2. Excluded studies
16	HPV‐020	NCT00586339	‐	Denny 2013	II	S‐Africa	18‐25y	150	HIV sero+ women: randomised to vaccine or placebo. Small group HIV sero‐ women: all received vaccine.	+	‐
1.3. Non published studies*
17	HPV‐003	NCT00263744	‐	‐	I/II	USA	18‐30y	60	Trial evaluating safety and immunogenicity in HPV16/18 DNA positive women. No data published	+	‐
18	HPV‐004	NCT00693615	‐	‐	II	USA	18‐30y	60	All randomised women received the HPV vaccine with ASO4 adjuvants, aluminium adjuvants or no adjuvants. There was no placebo control group who did not receive the bivalent vaccine.	+	‐
19	HPV‐005	NCT00693966	‐	‐	II	USA	18‐30y	210	Dose escalating trial without placebo group. There was no placebo control group who did not receive the bivalent vaccine.	+	‐
20	HPV‐012	NCT00169494	‐	‐	III	Europe	10‐25y	770	Trial evaluating lot‐to‐lot consistency and consistency with new manufacturing process.There was no placebo control group who did not receive the bivalent vaccine.	+	‐
										+	‐
									Total 1.1.‐1.3.	47,498
									In Cochrane review (1.1)	46,248	97.4%
									Not included in Cochrane review (1.2 + 1.3)	1,250	2.6%
1.4. Sub‐studies already included
21	HPV‐007 (HPV‐001 FU‐extension)	NCT00120848	Phase 2 trial (v2)	Romanowski 2009	IIb	Brazil, Canada, USA	15‐25y	776	‐	+	+
22	‐	NCT00456807	‐	‐	III	Netherlands	≥26y	100	Sub‐study of HPV‐015 investigating additional immunogenicity parameters in an included study.	+	‐
2.Quadrivalent vaccine
2.1. Published reports included in the Cochrane review
23	V501‐005	NCT00365378	Phase2 trial (1v)	Koutsky 2002 Mao 2006 Rowhani‐Rahbar 2009	II	USA	16‐23y	2392	‐	+	+
24	V501‐007	NCT00365716	Phase 2 trial (4v)	Villa 2005 Villa 2006 Villa 2006a	II	America, Europe	16‐23y	1158	‐	+	+
25	V501‐013	NCT00092521	Future I trial	Garland 2007	III	Asia‐Pacific, America, Europe	16‐24y	5455	‐	+	+
26	V501‐015	NCT00092534	FUTURE II trial	FUTURE‐II 2007	III	America, Asia, Europe	15‐26y	12,167	‐	+	+
27	V501‐019	NCT00090220	FUTURE III trial	Munoz 2009 Castellsagué 2011	III	America, Asia, Europe	24‐45y	3819	‐	+	+
28	V501‐023	NCT00157950	Korean trial (ph2,4v)	Kang 2008	III	Korea	9‐15y 16‐23y	176	‐	+	‐
29	V501‐027	NCT00378560	Japanese trial (ph2,4v)	Yoshikawa 2013	II	Japan	18‐26y	1021	‐	+	+
30	V501‐046	NCT01245764	African_3 country trial (ph3, 4v)	Mugo 2015	III	Ghana, Kenya, Senegal	Females 9‐26y	250	‐	+	‐
2.2. Excluded studies
31	V501‐018	NCT00092547	‐	Reisinger 2007	III	America, Europe Asia	Girls 9‐15y	939	Study included also male participants. Data could not be separated by gender.	+	‐
32	V501‐030	NCT00496626	‐	Li 2012	III	China	Females 9‐45y	400	Study included also male participants. Data could not be separated by gender. Request for data for female participants only was not answered	+	‐
2.3. Non published reports
									Total 2.1.‐2.3.	27,777
									Included in Cochrane review (2.1)	26,438	95.2%
									Not included in Cochrane review (2.2 + 2.3)	1339	4.8%
4. Sub‐studies already included
33	V501‐011	NCT00517309	FUTURE I trial sub	Wheeler 2008	III	Asia‐Pacific, America, Europe	16‐23 yrs	1877	‐	+	+
34	V501‐012	NCT00092482	FUTURE I sub	Garland 2007a	III	Asia‐Pacific, America, Europe	16‐23 yrs	3882	‐	+	+